Silence Therapeutics plc (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $33.83.

Several analysts recently weighed in on SLN shares. BMO Capital Markets lowered their price objective on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Chardan Capital lowered their target price on Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a report on Friday, May 9th. The Goldman Sachs Group lowered their target price on Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a report on Friday, May 9th. Morgan Stanley lowered their target price on Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 7th.

Silence Therapeutics Stock Performance

Silence Therapeutics stock traded up $0.36 during midday trading on Tuesday, reaching $4.37. The stock had a trading volume of 281,395 shares, compared to its average volume of 300,867. Silence Therapeutics has a twelve month low of $1.97 and a twelve month high of $24.38. The stock has a market capitalization of $130.79 million, a PE ratio of -2.78 and a beta of 1.20. The stock's 50-day simple moving average is $3.34 and its 200 day simple moving average is $5.93.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.58 million. Equities analysts predict that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Trading of Silence Therapeutics

Several hedge funds have recently modified their holdings of SLN. Barclays PLC increased its holdings in shares of Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Silence Therapeutics by 190.3% in the fourth quarter. Marshall Wace LLP now owns 488,889 shares of the company's stock valued at $3,364,000 after purchasing an additional 320,472 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $26,000. Nantahala Capital Management LLC increased its holdings in shares of Silence Therapeutics by 424.8% in the fourth quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock valued at $7,222,000 after purchasing an additional 849,676 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Silence Therapeutics by 50.5% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 128,990 shares of the company's stock valued at $887,000 after purchasing an additional 43,289 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company's stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.